Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission

Objective To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. Method Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed. Results Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% +/- 4.87% and 83.82% +/- 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% +/- 7.98% and 15.00% +/- 7.98%, respectively. Conclusion The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients.

Automated summary

This study evaluated the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. The results showed that auto-HSCT had excellent outcomes in these patients and could be an effective treatment for them.